David Mountcastle Sells 1,206 Shares of Privia Health Group (NASDAQ:PRVA) Stock

Privia Health Group, Inc. (NASDAQ:PRVA) CFO David Mountcastle sold 1,206 shares of the company’s stock in a transaction dated Monday, May 4th. The shares were sold at an average price of $25.00, for a total transaction of $30,150.00. Following the completion of the sale, the chief financial officer owned 214,847 shares in the company, valued at approximately $5,371,175. This trade represents a 0.56% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

David Mountcastle also recently made the following trade(s):

• On Friday, May 1st, David Mountcastle sold 7,179 shares of Privia Health Group stock. The stock was sold at an average price of $25.03, for a total value of $179,690.37.
• On Thursday, April 2nd, David Mountcastle sold 5,566 shares of Privia Health Group stock. The shares were sold at an average price of $20.85, for a total value of $116,051.10.
• On Monday, March 16th, David Mountcastle sold 6,391 shares of Privia Health Group stock. The stock was sold at an average price of $22.11, for a total value of $141,305.01.
• On Friday, March 13th, David Mountcastle sold 6,565 shares of Privia Health Group stock. The stock was sold at an average price of $21.52, for a total value of $141,278.80.
• On Thursday, March 12th, David Mountcastle sold 6,453 shares of Privia Health Group stock. The shares were sold at an average price of $21.90, for a total value of $141,320.70.
• On Monday, March 9th, David Mountcastle sold 5,829 shares of Privia Health Group stock. The shares were sold at an average price of $22.84, for a total value of $133,134.36.
• On Friday, March 6th, David Mountcastle sold 5,177 shares of Privia Health Group stock. The stock was sold at an average price of $23.15, for a total transaction of $119,847.55.
• On Thursday, February 26th, David Mountcastle sold 5,361 shares of Privia Health Group stock. The stock was sold at an average price of $25.00, for a total transaction of $134,025.00.
• On Friday, February 27th, David Mountcastle sold 7,697 shares of Privia Health Group stock. The stock was sold at an average price of $25.05, for a total transaction of $192,809.85.

Privia Health Group Stock Performance

NASDAQ PRVA opened at $23.99 on Thursday. Privia Health Group, Inc. has a one year low of $18.77 and a one year high of $26.51. The company has a 50-day simple moving average of $22.68 and a 200-day simple moving average of $23.35. The firm has a market capitalization of $3.01 billion, a PE ratio of 141.12, a price-to-earnings-growth ratio of 1.51 and a beta of 0.96.

Privia Health Group (NASDAQ:PRVA) last issued its earnings results on Thursday, May 7th. The company reported $0.19 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.08 by $0.11. Privia Health Group had a net margin of 1.08% and a return on equity of 3.06%. The firm had revenue of $603.85 million for the quarter, compared to analysts’ expectations of $560.99 million. Equities analysts forecast that Privia Health Group, Inc. will post 0.37 earnings per share for the current year.

Wall Street Analyst Weigh In

PRVA has been the topic of several analyst reports. Truist Financial increased their target price on Privia Health Group from $31.00 to $33.00 and gave the stock a “buy” rating in a research report on Monday, March 2nd. Evercore set a $26.00 price objective on shares of Privia Health Group in a report on Wednesday, April 8th. Jefferies Financial Group reissued a “buy” rating and set a $32.00 target price on shares of Privia Health Group in a research note on Thursday, February 26th. Barclays upped their target price on shares of Privia Health Group from $23.00 to $25.00 and gave the stock an “equal weight” rating in a research report on Wednesday, March 25th. Finally, Weiss Ratings restated a “hold (c)” rating on shares of Privia Health Group in a research note on Friday, March 27th. Eleven research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to data from MarketBeat.com, Privia Health Group has an average rating of “Moderate Buy” and a consensus price target of $31.31.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the business. Van Berkom & Associates Inc. lifted its holdings in Privia Health Group by 30.1% in the third quarter. Van Berkom & Associates Inc. now owns 3,774,565 shares of the company’s stock worth $93,987,000 after purchasing an additional 873,344 shares during the period. Vanguard Group Inc. increased its stake in Privia Health Group by 5.3% during the 3rd quarter. Vanguard Group Inc. now owns 12,098,933 shares of the company’s stock valued at $301,263,000 after buying an additional 607,447 shares during the period. ArrowMark Colorado Holdings LLC increased its stake in Privia Health Group by 139.4% during the 4th quarter. ArrowMark Colorado Holdings LLC now owns 841,266 shares of the company’s stock valued at $19,946,000 after buying an additional 489,866 shares during the period. Algert Global LLC raised its position in shares of Privia Health Group by 277.4% during the 3rd quarter. Algert Global LLC now owns 484,304 shares of the company’s stock worth $12,059,000 after buying an additional 355,966 shares in the last quarter. Finally, Freestone Grove Partners LP raised its position in shares of Privia Health Group by 40.6% during the 4th quarter. Freestone Grove Partners LP now owns 1,213,342 shares of the company’s stock worth $28,768,000 after buying an additional 350,194 shares in the last quarter. 94.48% of the stock is owned by institutional investors and hedge funds.

Key Privia Health Group News

Here are the key news stories impacting Privia Health Group this week:

• Positive Sentiment: Prior-quarter operating momentum: Privia beat expectations in its last report (Feb. 26) with $0.25 EPS vs. $0.04 est. and revenue of $541.2M (+17.4% YoY), which supports the view that growth and margin improvement are intact. Read More.
• Positive Sentiment: Analyst sentiment leans favorable: multiple firms (RBC, Truist, Jefferies, Wolfe) carry Buy/Outperform views and price targets near $31, indicating upside vs. the current share price. Read More.
• Neutral Sentiment: Q1 earnings is the main catalyst: Privia is scheduled to report Q1 results Thursday; investors will focus on revenue, patient volumes, margins and updated FY guidance — the release should determine the next directional move. Read More.
• Neutral Sentiment: Previews set expectations: recent previews outline items to watch (revenue mix, cost trends, value-based reimbursement progress); a clean beat could lift the stock, while conservative guidance could cap gains. Read More. Read More.
• Negative Sentiment: Insider sales by senior management: CFO David Mountcastle reported Rule 10b5‑1 sales (7,179 shares on May 1; 1,206 shares on May 4) — pre-arranged plans reduce governance concern but such disclosures can pressure near-term sentiment. Read More.
• Negative Sentiment: Director selling: Director Matthew Shawn Morris sold sizable blocks (17,096 on May 1 and 1,017 on May 4) under a 10b5‑1 plan, representing a material reduction in his position; this may weigh on sentiment despite the planned nature of the trades. Read More.

Privia Health Group Company Profile

Privia Health Group (NASDAQ: PRVA) is a physician enablement company that partners with independent physicians, medical groups and health systems to transform the delivery of patient care. Through a clinically integrated network and a proprietary technology platform, the company supports providers in managing population health, delivering coordinated care and optimizing financial performance under both fee-for-service and value-based reimbursement models.

Founded in 2016 and headquartered in McLean, Virginia, Privia Health has rapidly expanded its footprint to serve multiple metropolitan markets across the United States.